⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CGTX News
Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
globenewswire.com
CGTX
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
globenewswire.com
CGTX
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
globenewswire.com
CGTX
Form 8-K
sec.gov
CGTX
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
globenewswire.com
CGTX
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
globenewswire.com
CGTX
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
globenewswire.com
CGTX
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
globenewswire.com
CGTX
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
globenewswire.com
CGTX
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
globenewswire.com
CGTX